PALISADE BIO INC (PALI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.09+1.95%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PALI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | 0.3 | 0.0 | — | 0.0 | 0.0 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.4 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.3 | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.4 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.3 | — |
| R&D Expenses | — | — | — | — | — | — | 2.0 | 4.1 | 4.0 | 8.1 | 13.2 | 12.6 | 8.4 | 7.3 | 6.1 | 7.4 |
| Operating Income | (35.3) | (18.1) | (14.9) | (13.1) | (15.7) | (41.9) | (9.3) | (8.6) | (8.3) | (13.3) | (20.6) | (19.2) | (17.4) | (12.5) | (10.2) | (13.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 | 0.2 | 0.0 | 0.0 | 0.2 | 1.1 | 1.8 | 1.6 | 1.4 | 0.0 | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | 0.2 | (0.1) | (0.1) | 0.1 | 1.1 | 1.7 | 1.6 | 1.3 | (0.0) | (0.1) |
| Other Non-Operating Income / Expenses | 3.4 | 1.3 | 0.4 | 0.8 | 1.5 | 15.2 | (1.0) | 0.3 | 3.3 | (2.4) | (0.4) | (1.7) | (5.2) | (7.3) | 0.0 | 0.5 |
| Asset Writedown | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| Net Income | ||||||||||||||||
| Net Income | (31.9) | (16.8) | (14.4) | (12.3) | (14.3) | (26.6) | (10.3) | (8.4) | (4.9) | (15.7) | (21.1) | (20.9) | (22.6) | (19.8) | (10.1) | (12.5) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.15) | (0.30) | (10.19) | (27.01) | (16.53) | (142.95) | (3.72) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.15) | (0.30) | (10.19) | (27.01) | (16.53) | (169.74) | (3.72) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 211.4 | 55.7 | 1.4 | 0.5 | 0.9 | 0.2 | 2.8 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 211.4 | 55.7 | 1.4 | 0.5 | 0.9 | 0.2 | 2.8 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | (15.7) | (41.9) | (9.3) | (8.5) | (8.1) | (13.0) | (20.3) | (18.8) | (17.1) | (12.3) | (9.9) | (12.8) |
| EBIT | (35.3) | (18.1) | (14.9) | (13.1) | (15.7) | (41.9) | (9.3) | (8.6) | (8.3) | (13.3) | (20.6) | (19.2) | (17.4) | (12.5) | (10.2) | (13.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.